BEVERLY, MA–(Marketwired – November 16, 2015) - Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today reports that, based upon ongoing laboratory studies, the Company intends to use docetaxel for the combination therapy arm in the planned Phase 2 clinical trial to treat patients with platinum-resistance ovarian cancer. Cellceutix is designing the multi-arm study to evaluate Kevetrin as a monotherapy and as a component of combination therapy.
In planning the combination therapy arm of the study, several different chemotherapies were tested with Kevetrin. Nude mice were implanted with a human ovarian cancer tumor. After tumors were established, mice were treated with 200 mg/kg of Kevetrin in combination with docetaxel at 15 or 30 mg/kg. Interim findings showed that mice treated with Kevetrin in combination with 15 mg/kg docetaxel exhibited a significant reduction in tumor growth. Kevetrin in combination with 30 mg/kg docetaxel further reduced tumor burden.
Cellceutix finds it encouraging that 6 of 10 tumors in the group treated with the combination of Kevetrin and 30 mg/kg docetaxel have been reduced to the point that they are not measurable.
The experiment is still ongoing. The determination of the final docetaxel dose has not yet been determined, as the Company needs to take into consideration docetaxel toxicity. The final data from the research will be used to support the planned Phase 2 trial, which remains subject to Food and Drug Administration (FDA) guidance and authorization to initiate the trial.